Management of Paget's disease of bone in the era of new and more potent bisphosphonates.

@article{Siris1997ManagementOP,
  title={Management of Paget's disease of bone in the era of new and more potent bisphosphonates.},
  author={E. Siris},
  journal={Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists},
  year={1997},
  volume={3 4},
  pages={
          264-6
        }
}
  • E. Siris
  • Published 1997
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • The treatment of Paget’s disease of bone has entered a new era. With the development of newer and more potent bisphosphonate drugs—agents capable of actually “turning off” the pagetic bone remodeling abnormality for extended periods in many patients—physicians can now think about the indications for treatment in a new way. Most of us who treat Paget’s disease have been aggressive about using antipagetic therapy in patients who are symptomatic, and now, because of these new therapeutic options… CONTINUE READING
    5 Citations
    Paget’s Disease of Bone
    Paget's Disease of Bone (Osteitis Deformans)
    • 47
    Endocrinology of Aging
    • M. Conn
    • Contemporary Endocrinology
    • 2000
    Long-term efficacy and safety of pegvisomant therapy in acromegaly.
    • K. Yuen, L. Katznelson
    • Medicine
    • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    • 2015

    References

    SHOWING 1-10 OF 10 REFERENCES
    Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    • 210
    Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment.
    • 151
    Diphosphonate therapy of paget's disease of bone.
    • 150
    Effects of mithramycin on Paget's disease of bone.
    • 79